Terms: = Bone cancer AND CD52, CDW52, EDDM5 AND Treatment
31 results:
1. Dual targeting fixed duration frontline monoclonal antibody therapy for chronic lymphocytic leukemia: A phase 2 study.
Ma S; Rosen ST; Winqvist M; Frankfurt O; Winter JN; Gordon L; Helenowski I; Zhang H; Kreutzer J; Sönnert-Husa S; Österborg A; Lundin J
Leuk Res; 2022 Nov; 122():106945. PubMed ID: 36115087
[TBL] [Abstract] [Full Text] [Related]
2. CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia.
Hu Y; Zhou Y; Zhang M; Ge W; Li Y; Yang L; Wei G; Han L; Wang H; Yu S; Chen Y; Wang Y; He X; Zhang X; Gao M; Yang J; Li X; Ren J; Huang H
Clin Cancer Res; 2021 May; 27(10):2764-2772. PubMed ID: 33627493
[TBL] [Abstract] [Full Text] [Related]
3. Assessment of cd52 expression in "double-hit" and "double-expressor" lymphomas: Implications for clinical trial eligibility.
Craig JW; Mina MJ; Crombie JL; LaCasce AS; Weinstock DM; Pinkus GS; Pozdnyakova O
PLoS One; 2018; 13(7):e0199708. PubMed ID: 30020951
[TBL] [Abstract] [Full Text] [Related]
4. Universal monitoring of minimal residual disease in acute myeloid leukemia.
Coustan-Smith E; Song G; Shurtleff S; Yeoh AE; Chng WJ; Chen SP; Rubnitz JE; Pui CH; Downing JR; Campana D
JCI Insight; 2018 May; 3(9):. PubMed ID: 29720577
[TBL] [Abstract] [Full Text] [Related]
5. Allogeneic hematopoietic cell transplantation in T-cell prolymphocytic leukemia: A single-center experience.
Dholaria BR; Ayala E; Sokol L; Nishihori T; Chavez JC; Hussaini M; Kumar A; Kharfan-Dabaja MA
Leuk Res; 2018 Apr; 67():1-5. PubMed ID: 29407180
[TBL] [Abstract] [Full Text] [Related]
6. Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL.
Geisler CH; van T' Veer MB; Jurlander J; Walewski J; Tjønnfjord G; Itälä Remes M; Kimby E; Kozak T; Polliack A; Wu KL; Wittebol S; Abrahamse-Testroote MC; Doorduijn J; Ghidey Alemayehu W; van Oers MH
Blood; 2014 May; 123(21):3255-62. PubMed ID: 24735962
[TBL] [Abstract] [Full Text] [Related]
7. World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management.
Gotlib J
Am J Hematol; 2014 Mar; 89(3):325-37. PubMed ID: 24577808
[TBL] [Abstract] [Full Text] [Related]
8. Alemtuzumab for the prevention and treatment of graft-versus-host disease.
Kanda J; Lopez RD; Rizzieri DA
Int J Hematol; 2011 May; 93(5):586-593. PubMed ID: 21369856
[TBL] [Abstract] [Full Text] [Related]
9. Therapeutic potential of CAMPATH-1H in skeletal tumours.
Fritsche-Guenther R; Gruetzkau A; Noske A; Melcher I; Schaser KD; Schlag PM; Kasper HU; Krenn V; Sers C
Histopathology; 2010 Dec; 57(6):851-61. PubMed ID: 21166699
[TBL] [Abstract] [Full Text] [Related]
10. Alemtuzumab as a bridge to allogeneic SCT in atypical hemophagocytic lymphohistiocytosis.
Strout MP; Seropian S; Berliner N
Nat Rev Clin Oncol; 2010 Jul; 7(7):415-20. PubMed ID: 20404855
[TBL] [Abstract] [Full Text] [Related]
11. Circulating cd52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR).
Alatrash G; Albitar M; O'Brien S; Wang X; Manshouri T; Faderl S; Ferrajoli A; Burger J; Garcia-Manero G; Kantarjian HM; Lerner S; Keating MJ; Wierda WG
Br J Haematol; 2010 Feb; 148(3):386-93. PubMed ID: 19895616
[TBL] [Abstract] [Full Text] [Related]
12. Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of cancer and Leukemia Group B study 19901.
Byrd JC; Peterson BL; Rai KR; Hurd D; Hohl R; Perry MC; Gockerman J; Nattam S; Larson RA
Leuk Lymphoma; 2009 Oct; 50(10):1589-96. PubMed ID: 19863336
[TBL] [Abstract] [Full Text] [Related]
13. Alemtuzumab in the treatment of chronic lymphocytic lymphoma.
Boyd K; Dearden CE
Expert Rev Anticancer Ther; 2008 Apr; 8(4):525-33. PubMed ID: 18402519
[TBL] [Abstract] [Full Text] [Related]
14. Novel agents in the treatment of Waldenström's macroglobulinemia.
Treon SP; Hatjiharissi E; Leleu X; Moreau AS; Roccaro A; Hunter ZR; Soumerai JD; Ciccarelli B; Xu L; Sacco A; Ngo HT; Jia X; Yang C; Adamia S; Branagan AR; Ho AW; Santos DD; Tournilhac O; Manning RJ; Leduc R; O'Connor K; Nelson M; Patterson CJ; Ghobrial I
Clin Lymphoma Myeloma; 2007 Aug; 7 Suppl 5():S199-206. PubMed ID: 17877845
[TBL] [Abstract] [Full Text] [Related]
15. The diagnosis, management, and role of hematopoietic stem cell transplantation in aggressive peripheral T-cell neoplasms.
Rezania D; Cualing HD; Ayala E
Cancer Control; 2007 Apr; 14(2):151-9. PubMed ID: 17387300
[TBL] [Abstract] [Full Text] [Related]
16. Recent developments in new and old viral infections.
Gentile G
Rev Clin Exp Hematol; 2005 Dec; 9(2):E3. PubMed ID: 16864117
[TBL] [Abstract] [Full Text] [Related]
17. cd52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disorders.
Santos DD; Hatjiharissi E; Tournilhac O; Chemaly MZ; Leleu X; Xu L; Patterson C; Branagan AR; Manning RJ; Ho AW; Hunter ZR; Dimmock EA; Kutok JL; Churchill WH; Castells MC; Tai YT; Anderson KC; Treon SP
Clin Lymphoma Myeloma; 2006 May; 6(6):478-83. PubMed ID: 16796779
[TBL] [Abstract] [Full Text] [Related]
18. treatment of acute leukaemias with monoclonal antibodies: current status and future prospects.
Leone G; Sica S; Voso MT; Rutella S; Pagano L
Cardiovasc Hematol Agents Med Chem; 2006 Jan; 4(1):33-52. PubMed ID: 16529548
[TBL] [Abstract] [Full Text] [Related]
19. Drug therapy for the treatment of Langerhans cell histiocytosis.
McClain KL
Expert Opin Pharmacother; 2005 Nov; 6(14):2435-41. PubMed ID: 16259575
[TBL] [Abstract] [Full Text] [Related]
20. Myeloablative conditioning is well tolerated by older patients receiving T-cell-depleted grafts.
Novitzky N; Thomas V; Hale G; Waldmann H
Bone Marrow Transplant; 2005 Oct; 36(8):675-82. PubMed ID: 16113675
[TBL] [Abstract] [Full Text] [Related]
[Next]
